EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array

Steffen Jørgensen iD, Thorsten Brodersen, Ole Birger Vesterager Pedersen, Niels Westergaard iD

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14040 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Steffen Jørgensen and 3 co-authors. Institution: Centre for Engineering and Science, Department of Biomedical Laboratory Science, University College Absalon, Naestved, Denmark. Major MEDLINE topics: Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C9, Blood Donors. 20 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Cytochromes P450 (CYP450) drug metabolizing enzymes are the key enzymes in catalysing the oxidative biotransformation of 70%–80% of all drugs in clinical use to either inactive metabolites or active substances.1, 2 Polymorphism of genes encoding the CYP450 family of enzymes has attracted considerable attention as the major targets for pharmacogenomics (PGx) testing since they are highly polymorphic and thereby determining for drug response and adverse drug reactions (ADRs).3-5 CYP2C9 and CYP2C19 are both members of the CYP2C superfamily and located on chromosome 10. Both genes are highly polymorphic, and a large number of alleles have been identified in the human population.6, 7 These alleles are defined by specific single nucleotide polymorphisms (SNPs), which may affect enzyme function and thereby drug metabolism. CYP2C9 is involved in the metabolism of commonly used drugs, such as warfarin and the non-steroidal anti-inflammatory drugs (NSAIDs), for example, diclofenac and ibuprofen, whereas CYP2C19 is involved in the metabolism of, for example, clopidogrel, citalopram and proton pump inhibitors (PPIs).8 The most frequent CYP2C9 and CYP2C19 alleles beside the *1 allele found in the European population are CYP2C9*2 (430C > T, rs1799853) leading to decreased enzymatic function and CYP2C9*3 (1075A > C, rs1057910)9 with no function7 and for CYP2C19 the alleles are CYP2C19*2 (681G > A, rs4244285) with no function and CYP2C19*17 (−806C > T, rs12248560) having increased enzymatic function, due to enhanced gene expression.9 The Danish Blood Donor Study (DBDS) is a national prospective research cohort and biobank initiated in 2010 and became nationwide in 2015. The cohort consists of healthy blood donors for which questionnaire data and blood samples are collected upon inclusion.10, 11 The aim of this study was to compare and validate genotype data obtained with the Illumina Infinium Global Screening Array for CYP2C9 and CYP2C19 from 100 180 participants in the DBDS cohort against a random sample of 65 individuals of the same DBDS cohort, where the genotypes were additionally determined by using the ViennaLab CYP2C9 mpx RealFast PCR genotyping assay and 67 individuals were determined by using the Luminex xTAG CYP2C19 Kit v3 genotyping assay. In this study, CYP2C19*2 (c.681G > A, rs4244285), CYP2C19*17 (c.−806C > T, rs12248560), CYP2C9*2 (c.430C > T, rs1799853) and CYP2C9*3 (1075A > C, rs1057910) were measured in 100 180 individuals (DBDS freeze 20 210 503). The genome-wide genotyping was performed by deCODE (Reykjavik, Iceland) using Illumina's Infinium Global Screening Array v2.0 (Illumina, San Diego, California, USA), henceforth Illumina GSA, a high-density array with 654 027 fixed markers as well as a number of custom markers. The genotyping was based on DNA extraction from blood samples. For quality control, variants that did not satisfy Hardy–Weinberg equilibrium (HWE) at the cutoff p-value > 0.0001 and samples with a low genotype calling rate ( 0.05 were deemed to be in HWE, whereas a cutoff of p > 0.0001 was used for the chi-squared tests. All statistical analyses were performed using R v4.0.0.16 DBDS was approved by Zealand (SJ-740) and Central Denmark (1–10-72–95-13) Regional Committees on Health Research Ethics and the Data Protection Agency (P-2019–99). Ethics approval for registry data was not applicable according to Danish law since the use of anonymized healthcare data for pharmacoepidemiological research does not require subject consent or approval from the Ethics Committee. The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies.17 Genotype data were retrieved from 100 180 individuals in the DBDS cohort, and the prevalence of CYP2C19*2, CYP2C19*17, CYP2C9*2 and CYP2C9*3 was calculated and is shown in Table 1. Genetic variability of CYP2C19 and CYP2C9 is dominated by the CYP2C19*17 and CYP2C9*2 alleles compared to the CYP2C19*2 and CYP2C9*3 alleles, respectively, for both heterozygous and homozygous expression of the CYP2C19 and CYP2C9 genes. All genotyped variants were observed to be in HWE, except for CYP2C9*3, determined by Sanger sequencing (p = 0.047). All p-values from the exact and chi-squared tests for HWE are included in Tables 1 and 2. Table 2 shows the allele calls for specific CYP2C19 and CYP2C9 alleles on an individual level in a study population of 65 individuals for CYP2C9 and 67 individuals for CYP2C19, when comparing the genetic data obtained by the Sanger sequencing, the Illumina microarray and two commonly used PCR-based platforms, namely, the xTAG CYP2C19 assay and CYP2C9 RealFast PCR. One sample was excluded from the xTAG CYP2C19 dataset due to missing genotype calls. Two samples were excluded from the RealFast PCR CYP2C9 dataset due to missing genotype calls. As can be seen, only the Sanger sequencing identified homozygous star alleles for CYP2C9*3. When comparing the concordance between the platforms on an individual level, differences between allele callings of each allele investigated are displayed in Table 3. The highest degree of concordance was seen between the Illumina GSA and the Sanger sequencing, ranging from 98.4% to 100% when compared to the Illumina GSA and Luminex xTAG/RealFast PCR or the Sanger sequencing and Luminex xTAG/RealFast PCR. In this study, we explored existing genotype data for four CYP450 gene variants from the DBDS cohort, obtained using the Illumina GSA. The genotype distributions across the entire DBDS cohort was reported, consistent with previously reported findings for individuals of European ancestry.9 For example, the variant frequency for the effect allele for CYP2C9*2 (c.430C > T, rs1799853) was 12.27% in DBDS, while the gnomAD reported frequency is 13.19% for non-Finish Europeans and 11.42% for Finns.18 The genotypes were also compared to findings from different genotype protocols, Luminex xTAG (CYP2C19) and ViennaLab Realfast PCR (CYP2C9) and Sanger sequencing (CYP2C9 and CYP2C19), as shown in Table 3. Overall, we found the concordance rates for genotypes obtained by either Luminex xTAG or ViennaLab Realfast protocols and the Illumina GSA-based genotypes of DBDS to be low, 67.7%–94.0%, depending on SNP. It is worth noting that most of the disagreements arise from heterozygous variants being called homozygous and vice versa: 34/36 samples (94.4%) for Luminex and Illumina and 22/23 samples (95.7%) for ViennaLab and Illumina. The remaining few disagreements are called wildtypes on one platform but homozygous for the effect allele on the alternative platform. Sanger sequencing was used as a reference, and we assumed these genotypes to be the true genotypes for each sample, with one notable exception, as the Sanger sequencing results for CYP2C9*3 did not meet HWE (Table 2). Our results showed almost complete concordance between the genotypes obtained by Sanger sequencing and the Illumina GSA; only for CYP2C9*3 (1075 C/C) did we see a single sample called differently on the two platforms (Table 2). Interestingly, this specific sample was called homozygous for the effect allele using Sanger sequencing but as a wildtype on both the ViennaLab and Illumina platforms. Due to the low occurrence of the effect allele for CYP2C9*3 in conjunction with the low sample size, this homozygous call was likely the reason why HWE was not observed for the CYP2C9*3 genotyping results obtained by Sanger sequencing. Our findings suggest that the Illumina GSA obtained the correct genotypes, while the Luminex and ViennaLab platforms got some level of erroneous calls, especially with regards to distinguishing homozygous and heterozygous samples. For Illumina GSA, this is consistent with previous reports showing the platform to have high concordance with existing and known data, with slight variations depending on the exact DNA input, methodology and algorithm for calling the genotypes.19, 20 We believe the current study to be important for highlighting the possible use of existing genotype data for pharmacogenetics. However, it should be noted that this study features a very modest sample size and that this is a major constraint. While the evidence is compelling, larger sample sizes may be needed to substantiate all the observations described in this manuscript. In conclusion, the distribution of four CYP450 gene variants, CYP2C19*2 (c.681G > A, rs4244285), CYP2C19*17 (c.−806C > T, rs12248560), CYP2C9*2 (c.430C > T, rs1799853) and CYP2C9*3 (1075A > C, rs1057910), in the DBDS cohort is consistent with known genotype distributions. When comparing genotyping results from Illumina GSA and Luminex xTAG or ViennaLab Realfast PCR using Sanger sequencing as a reference, the Luminex and ViennaLab platforms performed the worst, with several incorrect calls. These inconsistent genotype calls were more likely to stem from erroneous calling of heterozygous versus homozygous genotypes. This means that using the Illumina GSA could be a valuable tool in the DBDS to identify clinically relevant drug–gene and drug–drug–gene interactions based on clinical outcome. All authors contributed to the study's conception and design according to journal author guidelines and the ICMJE definition of authorship. This study was performed using the Danish Blood Donor Study cohort, and we thank the staff and blood donors who participated in the study. The authors declare no competing interests. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Table S1: Primers used for PCR amplification and Sanger sequencing Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Blood DonorsHumansDenmarkAllelesCohort StudiesMaleFemaleGene FrequencyPolymorphism, Single NucleotideAdult

Author keywords

CYP2C19CYP2C9biobankcytochrome P450genotypemicroarraypharmacogenomicsqPCR

Substances

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9CYP2C19 protein, humanCYP2C9 protein, human

Authors and institutions

  • Centre for Engineering and Science, Department of Biomedical Laboratory Science, University College Absalon, Naestved, Denmark.
  • Department of Clinical Immunology, Zealand University Hospital Køge, Køge, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Centre for Nursing, University College Absalon, Roskilde, Denmark.

ORCID profiles: Steffen Jørgensen, Niels Westergaard

Cite

APA

Jørgensen, S., Brodersen, T., Vesterager Pedersen, O. B., & Westergaard, N. (2024). Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14040

Vancouver

Jørgensen S, Brodersen T, Vesterager Pedersen OB, Westergaard N. Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14040

BibTeX
@article{Jrgensen2024,
  author = {Jørgensen, Steffen and Brodersen, Thorsten and Vesterager Pedersen, Ole Birger and Westergaard, Niels},
  title = {Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14040}
}
Start for free →